Physician profile
Christopher M Cooper
NPI 1770565467
$2,585.69
in general payments reported to CMS, 2019-2025
25 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Adult Medicine provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $191 · 2021: $329 · 2022: $304 · 2023: $659 · 2024: $386 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,162.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $657.21 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $442.40 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $214.59 | 2019-2025 | Livtencity |
| Glaxosmithkline, LLC. | $206.59 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Exact Sciences Corporation | $155.10 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $129.95 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $120.00 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $112.67 | 2019-2024 | Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $102.24 | 2019-2021 | |
| Smith+Nephew, INC. | $98.60 | 2023 | Pico, Renasys Touch |
| Novartis Pharmaceuticals Corporation | $42.56 | 2019 | |
| Allergan, INC. | $35.68 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.21 | 2020-2021 | |
| Abbott Laboratories | $34.78 | 2023-2024 | Proclaim |
| Amgen INC. | $33.02 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $24.53 | 2023 | Quviviq |
| Astellas Pharma US INC | $23.48 | 2019 | |
| Paratek Pharmaceuticals, INC. | $17.89 | 2020 | |
| Horizon Therapeutics Plc | $17.21 | 2019 | |
| Merck Sharp & Dohme LLC | $16.33 | 2019 | |
| Amarin Pharma, INC. | $15.54 | 2019 | |
| Vertiflex, INC. | $13.34 | 2019 | |
| Strongbridge US INC. | $13.34 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.72 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.